Automation of cellular combination screening to identify novel cancer therapies
Harry Woodcock, Senior Research Associate, Vertex Pharmaceutical, Ltd.
Introducing automation and scheduling software can improve throughput, increase robustness and reduce errors in cellular and biochemical assays to support drug discovery. We routinely perform a number of drug combination assays on panels of cancer cell lines to define novel synergistic and antagonistic relationships between small molecule inhibitors and existing cancer therapies. Cell proliferation and viability provide robust endpoints for such assays, however large manual combination screens are highly labour intensive, time-sensitive and subject to human error. Here we describe the full automation of combination assays for Oncology. The workcell has considerably increased the throughput of these assays while reducing risk of failure and analysis time.
Scaling a factory: leveraging GBG to create a single, data-driven interface across small and large automation platforms
John Cesarek, Principal Engineer, Zymergen, Inc.
Scaling complex workflows across multiple project types on small and large automation platforms creates challenges within an automation environment. Integrating GBG to a custom LIMS environment allows protocol workflow steps and process parameters to be simplified to a one-click operation. Through the implementation of a unified front-end, the user has a consistent experience across all systems. This presentation will address the development of a unified front-end using GBG’s API’s, C# scripts and conditional procedures to provide a seamless data-driven experience for the end-user. An overview of how to use GBG for data-driven hitpicking workflows within a fully automated acoustic liquid handing platform will be provided and the presenter will highlight how the implementation of the aforementioned systems create a more simplified and efficient process.